Beta-2 Adrenergic Receptor

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
<StructureSection load='1dq8' size='490' side='right' caption='Solved Structures of a Beta 2-Adrenergic Receptor' scene=' ' >
<StructureSection load='1dq8' size='490' side='right' caption='Solved Structures of a Beta 2-Adrenergic Receptor' scene=' ' >
-
[[Image: |120px|left]]&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; [[Beta-2 Adrenergic Receptor]]'''s''' (B2ARs) are a type of G Protein-Coupled Receptor (GPCR). GPCRs are the largest family of integral membrane proteins in the human body with over 1000 unique Isoforms. B2AR is activated by hormone ligands like adrenaline (epinephrine) and noradrenaline and plays a critical role in cardiovascular and pulmonary physiology. Binding of adrenaline by B2AR causes a sympathetic nervous system response like the well-known “flight or flight response”, resulting in an increased heart rate, pupil dilation, rapid energy mobilization and diversion of blood to skeletal muscle. More precisely, upon binding a ligand, B2AR activates [[Adenylyl cyclase]] through interaction with B2ARs C-terminus. Adenylyl cyclase subsequently converts ATP into cAMP, which functions as a downstream signaling molecule activating effectors like cAMP-dependent protein kinases, resulting in various bodily responses.<ref name="Witter"/>
+
[[Image:|120px|left]]&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; [[Beta-2 Adrenergic Receptor]]'''s''' (B2ARs) are a type of G Protein-Coupled Receptor (GPCR). GPCRs are the largest family of integral membrane proteins in the human body with over 1000 unique Isoforms. B2AR is activated by hormone ligands like adrenaline (epinephrine) and noradrenaline and plays a critical role in cardiovascular and pulmonary physiology. Binding of adrenaline by B2AR causes a sympathetic nervous system response like the well-known “flight or flight response”, resulting in an increased heart rate, pupil dilation, rapid energy mobilization and diversion of blood to skeletal muscle. More precisely, upon binding a ligand, B2AR activates [[Adenylyl cyclase]] through interaction with B2ARs C-terminus. Adenylyl cyclase subsequently converts ATP into cAMP, which functions as a downstream signaling molecule activating effectors like cAMP-dependent protein kinases, resulting in various bodily responses.<ref name="Witter"/>
====B2AR and Autism====
====B2AR and Autism====
Line 13: Line 13:
====Pharmaceutical Implications====
====Pharmaceutical Implications====
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although activation of B2AR upon ligand binding is not fully understood, a recently solved structure of Beta 1 Adrenergic Receptors offers clues. Agonists of B1ARs disrupt the interaction between Val 172 and Ser 215, eliminating a key interaction between helices four and five. Since mutation to Val 172 is known to reduce basal activity, it is likely that the agonists interference of Val 172 has a similar affect.<ref>PMID: 21228877</ref> The class of [[Pharmaceutical Drugs|pharmaceutical drugs]] known as the “beta blockers” are antagonists of B2AR. They diminish the effects of adrenaline, slowing the heart rhythm and reducing blood pressure. B2AR Agonists serve a completely different purpose. These molecules which mimic native ligands of B2AR cause smooth muscle relaxation, bronchial passage dilation, vasodilation and rapid release of insulin. These compounds are used to treat asthma, and include the well-known Albuterol and Terbutaline.<ref>PMID: 20692524</ref>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although activation of B2AR upon ligand binding is not fully understood, a recently solved structure of Beta 1 Adrenergic Receptors offers clues. Agonists of B1ARs disrupt the interaction between Val 172 and Ser 215, eliminating a key interaction between helices four and five. Since mutation to Val 172 is known to reduce basal activity, it is likely that the agonists interference of Val 172 has a similar affect.<ref>PMID: 21228877</ref> The class of [[Pharmaceutical Drugs|pharmaceutical drugs]] known as the “beta blockers” are antagonists of B2AR. They diminish the effects of adrenaline, slowing the heart rhythm and reducing blood pressure. B2AR Agonists serve a completely different purpose. These molecules which mimic native ligands of B2AR cause smooth muscle relaxation, bronchial passage dilation, vasodilation and rapid release of insulin. These compounds are used to treat asthma, and include the well-known Albuterol and Terbutaline.<ref>PMID: 20692524</ref>
 +
__NOTOC__
 +
__NOEDITSECTION__
</StructureSection>
</StructureSection>
==References==
==References==
<references/>
<references/>

Revision as of 04:34, 3 April 2011

Solved Structures of a Beta 2-Adrenergic Receptor

Drag the structure with the mouse to rotate

References

  1. 1.0 1.1 1.2 Witter FR, Zimmerman AW, Reichmann JP, Connors SL. In utero beta 2 adrenergic agonist exposure and adverse neurophysiologic and behavioral outcomes. Am J Obstet Gynecol. 2009 Dec;201(6):553-9. PMID:19961985 doi:10.1016/j.ajog.2009.07.010
  2. 2.0 2.1 Mehler MF, Purpura DP. Autism, fever, epigenetics and the locus coeruleus. Brain Res Rev. 2009 Mar;59(2):388-92. Epub 2008 Nov 24. PMID:19059284 doi:10.1016/j.brainresrev.2008.11.001
  3. Rasmussen SG, Choi HJ, Rosenbaum DM, Kobilka TS, Thian FS, Edwards PC, Burghammer M, Ratnala VR, Sanishvili R, Fischetti RF, Schertler GF, Weis WI, Kobilka BK. Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. Nature. 2007 Nov 15;450(7168):383-7. Epub 2007 Oct 21. PMID:17952055 doi:10.1038/nature06325
  4. Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, Choi HJ, Kuhn P, Weis WI, Kobilka BK, Stevens RC. High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science. 2007 Nov 23;318(5854):1258-65. Epub 2007 Oct 25. PMID:17962520
  5. Hanson MA, Cherezov V, Griffith MT, Roth CB, Jaakola VP, Chien EY, Velasquez J, Kuhn P, Stevens RC. A specific cholesterol binding site is established by the 2.8 A structure of the human beta2-adrenergic receptor. Structure. 2008 Jun;16(6):897-905. PMID:18547522 doi:10.1016/j.str.2008.05.001
  6. Scheerer P, Park JH, Hildebrand PW, Kim YJ, Krauss N, Choe HW, Hofmann KP, Ernst OP. Crystal structure of opsin in its G-protein-interacting conformation. Nature. 2008 Sep 25;455(7212):497-502. PMID:18818650 doi:10.1038/nature07330
  7. Warne T, Moukhametzianov R, Baker JG, Nehme R, Edwards PC, Leslie AG, Schertler GF, Tate CG. The structural basis for agonist and partial agonist action on a beta(1)-adrenergic receptor. Nature. 2011 Jan 13;469(7329):241-4. PMID:21228877 doi:10.1038/nature09746
  8. Cruickshank JM. Beta blockers in hypertension. Lancet. 2010 Aug 7;376(9739):415; author reply 415-6. PMID:20692524 doi:10.1016/S0140-6736(10)61217-2
Personal tools